Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, two-stage, multi-arm, phase 1/2 trial-Reference-Cited by-同舟云学术

Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, two-stage, multi-arm, phase 1/2 trial

Published:2016-11 Issue:11 Volume:17 Page:1590-1598
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Sharma Padmanee,Callahan Margaret K,Bono Petri,Kim Joseph,Spiliopoulou Pavlina,Calvo Emiliano,Pillai Rathi N,Ott Patrick A,de Braud Filippo,Morse Michael,Le Dung T,Jaeger Dirk,Chan Emily,Harbison Chris,Lin Chen-Sheng,Tschaika Marina,Azrilevich Alex,Rosenberg Jonathan E

Funder

NIH/NCI Cancer Center Support

Publisher

Elsevier BV

Subject

Oncology

Reference30 articles.

1. A prospective randomized trial comparing MVAC and CISCA chemotherapy for patients with metastatic urothelial tumors;Logothetis;J Clin Oncol,1990

2. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study;von der Maase;J Clin Oncol,2000

3. Randomized phase III study comparing paclitaxel/cisplatin/gemcitabine and gemcitabine/cisplatin in patients with locally advanced or metastatic urothelial cancer without prior systemic therapy: EORTC Intergroup Study 30987;Bellmunt;J Clin Oncol,2012

4. Impact of renal impairment on eligibility for adjuvant cisplatin-based chemotherapy in patients with urothelial carcinoma of the bladder;Dash;Cancer,2006

5. Long-term survival results of a randomized phase III trial of vinflunine plus best supportive care versus best supportive care alone in advanced urothelial carcinoma patients after failure of platinum-based chemotherapy;Bellmunt;Ann Oncol,2013

Cited by 611 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Novel therapeutic regimens in previously untreated metastatic urothelial carcinoma: A systematic review and bayesian network meta-analysis;Urologic Oncology: Seminars and Original Investigations;2024-11

2. Efficacy and Safety of Iparomlimab, an Anti-PD-1 Antibody, in Patients with Advanced Solid Tumors: A Phase 1c Study;Advances in Therapy;2024-09-14

3. Efficacy and safety of adjuvant nivolumab after radical surgery for high-risk urothelial carcinoma: a preliminary report of real-world data from a single institution;International Journal of Clinical Oncology;2024-09-12

4. An Overview of Immune Checkpoint Inhibitor Toxicities in Bladder Cancer;Toxicology Reports;2024-09